The purpose of this study is to evaluate the dose-response relationship (effect) of four concentrations of V-101 Cream in patients with erythematous(redness) rosacea.

Patients must have moderate to severe erythematous (facial redness) rosacea

• Male and female patients must be at least 18 years old and in good general health
• Female patients must not be pregnant or nursing

Inclusion Criteria:

• male or females at least 18 years of age
• diagnosis of stable erythematous rosacea
• < 3 inflammatory lesions
• in good general health
• females must be non-pregnant and non-lactating
• must be willing to sign a consent form

Exclusion Criteria:

• have ocular, phymatous or other types of rosacea
• allergy to any ingredient in study drug
• participation in other investigational studies within 30 days of enrollment
• use of systemic steroids within 28 days of Baseline
• use of tetracycline antibiotics within 28 days of baseline
• use of products containing oxymetazoline within 14 days of baseline
• use of topical steroids witin treatment area 14 days prior to baseline
• use of Rx or OTC products for treatment of acne or rosacea within 14 days of baseline
• use of any product for reducing redness within the treatment area witin 14 days prior to baseline
• use of monoamine oxidase (MAO) inhibitors
• use of niacin >/= 500mg/day